Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Anti-Infective Agents

Central Nervous System Depressants

Antineoplastic Agents

Herbal and Botanical

Liver Extracts

Ethanol

Sorafenib

Protein Kinase Inhibitors

Enzyme Inhibitors

Anti-Infective Agents, Local

European Mistletoe

Progressive (deteriorate/Recurrence) or Death

Radiofrequency ablation

Trance-arterial chemoembolization

non-anatomical or anatomical liver resection

Liver resection

Combined radiofrequency ablation + percutaneous ethanol injection

Percutaneous ethanol injection

Systemic chemotherapy

Viscum

Symptomatic treatment

Emad A. Ahmed, MD, PhD

EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.

Background:

EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma (HCC) who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.

Methods:

This work was conducted at the departments of tropical medicine and gastroenterology, internal medicine, and general surgery. This study included patients that matched our eligibility criteria for a period of five years started from June 2015 to May 2020. The study purpose was to retrospectively analyze the clinical outcomes among patients with HCC who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment favorable outcomes. The data of the patients were extracted and retrospectively reviewed from the patients' records and the databases of both hospitals (SUH and SOI).

During the period of recruitment, 407 patients diagnosed with HCC admitted to our departments and followed-up attending outpatient clinics, Sohag University Hospitals, over a 5 years period.

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma

the HCC is treated (disappearance of all lesions)

increase in size - appearance of new intratumoral lesions - new lesions

Sohag University

Principal investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma	NCT04553458	Hepatocellular ...	Radiofrequency ... Trance-arterial... Liver resection Combined radiof... Percutaneous et... Systemic chemot... Sorafenib Viscum Symptomatic tre...	18 Years -	Sohag University
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma	NCT04553458	Hepatocellular ...	Radiofrequency ... Trance-arterial... Liver resection Combined radiof... Percutaneous et... Systemic chemot... Sorafenib Viscum Symptomatic tre...	18 Years -	Sohag University

Spots Global Cancer Trial Database for primary liver tumours